cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Chinook Therapeutics Inc
1 own
3 watching
Current Price
$24.08
$-1.27
(-5.01%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,536.83M
52-Week High
52-Week High
27.44
52-Week Low
52-Week Low
11.81
Average Volume
Average Volume
0.52M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,536.83M
icon52-Week High27.44
icon52-Week Low11.81
iconAverage Volume0.52M
iconDividend Yield--
iconP/E Ratio--
What does the Chinook Therapeutics Inc do?
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company s lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Read More
How much money does Chinook Therapeutics Inc make?
News & Events about Chinook Therapeutics Inc.
Globe Newswire
3 months ago
BION-1301 Treatment Results in Rapid and Durable Reductions in IgA and Gd-IgA1 in Patients with IgA Nephropathy Following both IV and SC dosing, BION-1301 produced rapid and sustained reductions in IgA and Gd-IgA1, the pathogenic variant of IgA nephropathy BION-1301 Treatment Results in ...
Globe Newswire
3 months ago
Atrasentan Treatment Results in Clinically Meaningful Proteinuria Reductions in Patients with IgAN Treatment with atrasentan results in durable and clinically meaningful proteinuria reductions in patients with IgAN receiving optimized standard of care Atrasentan was well-tolerated with no ...
Globe Newswire
3 months ago
Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial Additional interim data to be presented from Cohorts 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Research presentations include the ...
Ticker Report
5 months ago
Chinook Therapeutics (NASDAQ:KDNY Get Rating) had its target price hoisted by HC Wainwright from $28.00 to $32.00 in a research report report published on Monday morning, MarketBeat reports. They currently have a buy rating on the stock. KDNY has been the topic of a number of other reports. ...
Globe Newswire
7 months ago
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for ...
Frequently Asked Questions
Frequently Asked Questions
What is Chinook Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Chinook Therapeutics Inc shares?
plus_minus_icon
How can I buy Chinook Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Chinook Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Chinook Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Chinook Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Chinook Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Chinook Therapeutics Inc?
plus_minus_icon
What percentage is Chinook Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Chinook Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$24.08
$-1.27
(-5.01%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00